Chapter 1: Evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022

No abstract is available for this paper.

• Publication year

  2023

• Venue

  International Journal of Clinical Oncology

• Publication date

  2023-06-29

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10147-023-02372-4PMID 37382749
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022

  2023cited by this paper
• Cisplatin‐induced nephrotoxicity in an outpatient setting

  2021cited by this paper
• Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor

  2021cited by this paper
• Reversible renal-limited thrombotic microangiopathy due to gemcitabine-dexamethasone-cisplatin therapy: a case report

  2021cited by this paper
• Clinicopathologic Features of Acute Kidney Injury Associated With CDK4/6 Inhibitors

  2021cited by this paper
• A digest of the Evidence-Based Clinical Practice Guideline for Nephrotic Syndrome 2020

  2021cited by this paper
• Nephrotoxicity of Anti-Angiogenic Therapies

  2021cited by this paper
• Prevalence and Prognostic Significance of Hyponatremia in Patients With Lung Cancer: Systematic Review and Meta-Analysis

  2021cited by this paper
• Hypophosphatemia in cancer patients

  2021cited by this paper
• Mean of creatinine clearance and urea clearance examined over 1 h estimates glomerular filtration rate accurately and precisely in children

  2021cited by this paper
• Acute kidney injury as a risk factor for mortality in oncological patients receiving check-point inhibitors.

  2021cited by this paper
• Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non–Small-Cell Lung Cancer

  2021cited by this paper
• Incidence and risk factors of acute kidney injury, and its effect on mortality among Japanese patients receiving immune check point inhibitors: a single-center observational study

  2021cited by this paper
• Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study.

  2021cited by this paper
• Non-steroidal Anti-inflammatory Drugs Are a Risk Factor for Cisplatin-induced Nephrotoxicity: A Meta-analysis of Retrospective Studies

  2020cited by this paper
• Cumulative cancer incidence and mortality after kidney transplantation in Japan: A long‐term multicenter cohort study

  2020cited by this paper
• Hypomagnesemia in the Cancer Patient.

  2020cited by this paper
• Risk and impact of delayed renal impairment in patients with locally advanced head and neck squamous cell carcinoma receiving chemoradiotherapy with cisplatin

  2020cited by this paper
• Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes

  2020cited by this paper
• Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma.

  2020cited by this paper
• Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study.

  2020influential reference
• Clinical recommendations on diagnosis and treatment of immune checkpoint inhibitor‐induced renal immune‐related adverse events

  2020cited by this paper
• Cumulative pemetrexed dose increases the risk of nephrotoxicity.

  2020cited by this paper
• Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

  2020cited by this paper
• Proteinuria is a late-onset adverse event in patients treated with cabozantinib

  2020cited by this paper
• Toxicity, risk factors and management of cisplatin-induced toxicity: A prospective study

  2020cited by this paper
• Kidney Biopsy Should Be Performed to Document the Cause of Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: CON.

  2020cited by this paper
• Risk factors for renal toxicity after inpatient cisplatin administration

  2020cited by this paper
• How to assess kidney function in oncology patients.

  2020cited by this paper
• Donor-transmitted cancer in kidney transplant recipients: a systematic review

  2020cited by this paper
• Onconephrology: The intersections between the kidney and cancer

  2020cited by this paper
• Risk Factors for Acute Kidney Injury During High-dose Chemotherapy and Outcomes for Patients With Relapsed Germ Cell Tumors.

  2020cited by this paper
• GFR Measurement and Chemotherapy Dosing in Patients with Kidney Disease and Cancer.

  2020cited by this paper
• Death after Kidney Transplantation: An Analysis by Era and Time Post-Transplant.

  2020cited by this paper
• Hypernatremia at admission predicts poor survival in patients with terminal cancer: a retrospective cohort study

  2020cited by this paper
• Acute kidney injury in patients treated with anti-programmed death receptor-1 for advanced melanoma: a real-life study in a single-centre cohort.

  2020cited by this paper
• Association between chronic kidney disease and mortality in stage IV cancer

  2020cited by this paper
• Risk Factors for Cisplatin-Induced Nephrotoxicity: A Multicenter Retrospective Study.

  2020cited by this paper
• New Concept of Onco-Hypertension and Future Perspectives

  2020cited by this paper
• A Systematic Review of Immune Checkpoint Inhibitor–Associated Glomerular Disease

  2020cited by this paper
• An evidence-based clinical practice guideline

  2020cited by this paper
• Kidney Biopsy Should Be Performed to Document the Cause of Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: PRO.

  2020cited by this paper
• Risk factors for high‐dose methotrexate associated acute kidney injury in patients with hematological malignancies

  2020cited by this paper
• Hyponatremia and other electrolyte abnormalities in patients receiving immune checkpoint inhibitors.

  2020influential reference
• Drug-Induced Hypertension Caused by Multikinase Inhibitors (Sorafenib, Sunitinib, Lenvatinib and Axitinib) in Renal Cell Carcinoma Treatment

  2019cited by this paper
• Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.

  2019cited by this paper
• Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?

  2019cited by this paper
• Kyoto, Japan

  2019cited by this paper
• Therapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities.

  2019cited by this paper
• Cancer‐attributable mortality among solid organ transplant recipients in the United States: 1987 through 2014

  2019cited by this paper
• Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients.

  2019cited by this paper
• Renal toxicity with mammalian target of rapamycin inhibitors: A meta-analysis of randomized clinical trials

  2019cited by this paper
• Disruption of podocyte cytoskeletal biomechanics by dasatinib leads to nephrotoxicity

  2019cited by this paper
• Incidence, Risk Factors, and Clinical Outcomes of Acute Kidney Injury Caused by Palliative Chemotherapy in Lung Cancer

  2019cited by this paper
• The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors.

  2019cited by this paper
• Estimated Glomerular Filtration Rate and the Risk of Cancer.

  2019cited by this paper
• Summary of the International Conference on Onco-Nephrology: an emerging field in medicine.

  2019cited by this paper
• Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence.

  2019cited by this paper
• Dose recommendations for anticancer drugs in patients with renal or hepatic impairment.

  2019cited by this paper
• Evaluation of Acute Kidney Injury Associated With Anticancer Drugs Used in Gastric Cancer in the Japanese Adverse Drug Event Report Database

  2019cited by this paper
• Incidence and risk factors for acute kidney injury in head and neck cancer patients treated with concurrent chemoradiation with high-dose cisplatin

  2019cited by this paper
• Ibrutinib induced acute tubular injury: A case series and review of the literature

  2019cited by this paper
• Biological variation of measured and estimated glomerular filtration rate in patients with chronic kidney disease.

  2019cited by this paper
• Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience

  2019cited by this paper
• Estimation of Kidney Function in Oncology: Implications for Anticancer Drug Selection and Dosing.

  2019cited by this paper
• Ifosfamide nephrotoxicity in adult patients

  2019influential reference
• Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis

  2019cited by this paper
• Hypertension and Incident Cardiovascular Events Following Ibrutinib Initiation.

  2019cited by this paper
• Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.

  2019cited by this paper
• Acute kidney injury predicts all‐cause mortality in patients with cancer

  2019cited by this paper
• Electrolyte disorders in cancer patients: a systematic review

  2019cited by this paper
• Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma

  2019cited by this paper
• Impact of aging on the risk of platinum-related renal toxicity: A systematic review and meta-analysis.

  2018cited by this paper
• Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

  2018cited by this paper
• Renal impairment during pemetrexed maintenance in patients with advanced nonsmall cell lung cancer: a cohort study

  2018cited by this paper
• The characteristics and risk factors for cisplatin-induced acute kidney injury in the elderly

  2018cited by this paper
• The Japanese clinical practice guideline for acute kidney injury 2016

  2018cited by this paper
• Efficacy and safety of sunitinib in elderly patients with advanced renal cell carcinoma.

  2018cited by this paper
• Predisposing factors for chemotherapy-induced nephrotoxicity in patients with advanced esophageal cancer who received combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil

  2018cited by this paper
• Ifosfamide

  2018cited by this paper
• Chemotherapy in cancer patients undergoing haemodialysis: a nationwide study in Japan

  2018cited by this paper
• Characteristic morphological changes in anti‐VEGF therapy‐induced glomerular microangiopathy

  2018cited by this paper
• Pragmatic Use of Kidney Function Estimates for Drug Dosing: The Tide Is Turning.

  2018cited by this paper
• Assessment of Kidney Function in Patients With Cancer.

  2018cited by this paper
• 5. Nephrotoxicity of Chemotherapy Agents

  2018cited by this paper
• Hungry bone syndrome secondary to prostate cancer successfully treated with radium therapy

  2018cited by this paper
• Bevacizumab-associated glomerular microangiopathy

  2018cited by this paper
• Development and Validation of a Risk Prediction Model for Acute Kidney Injury After the First Course of Cisplatin.

  2018cited by this paper
• Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort

  2018cited by this paper
• Acute Kidney Injury in Patients Receiving Systemic Treatment for Cancer: A Population-Based Cohort Study.

  2018cited by this paper
• The Japanese Clinical Practice Guideline for acute kidney injury 2016

  2018cited by this paper
• Progressive renal insufficiency related to ALK inhibitor, alectinib

  2018cited by this paper
• Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2018cited by this paper
• Electrolyte Disturbances in Critically Ill Cancer Patients: An Endocrine Perspective

  2018cited by this paper
• Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate

  2018cited by this paper
• Cancer and mTOR Inhibitors in Transplant Recipients.

  2017cited by this paper
• Risk Factors for Nephrotoxicity Associated with Cisplatin.

  2017cited by this paper
• Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome‐Positive Leukemias

  2017cited by this paper
• Epidemiology of cancer in end-stage renal disease dialysis patients: a national cohort study in Taiwan

  2017cited by this paper
• Renal failure during chemotherapy: renal biopsy for assessing subacute nephrotoxicity of pemetrexed

  2017cited by this paper

• Onco-nephrology in clinical practice: pharmacokinetics, monitoring, and treatment strategies for patients with cancer and impaired renal function

  2025cites this paper
• Impact of baseline renal impairment on severe neutropenia development in pemetrexed and carboplatin thoracic cancer treatment

  2024influential citation
• Development of Artificial Intelligence Systems for Chronic Kidney Disease

  2024cites this paper
• Bevacizumab-Induced Nephropathy Presenting as Crescentic Glomerulopathy

  2023cites this paper
• Chapter 4: CKD treatment in cancer survivors, from Clinical Practice Guidelines for the Management of Kidney Injury During Anticancer Drug Therapy 2022

  2023cites this paper
• Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022

  2023cites this paper
• Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022

  2023cites this paper
• World Journal of Gastroenterology

  year unknowncites this paper